LSE - Delayed Quote GBp
Ondine Biomedical Inc. (OBI.L)
9.00
-0.25
(-2.70%)
As of 2:00:25 PM GMT+1. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
1,203
1,203
638
2,569
1,791
Cost of Revenue
500
500
351
1,315
1,142
Gross Profit
703
703
287
1,254
649
Operating Expense
15,508
15,508
19,050
18,774
16,520
Operating Income
-14,805
-14,805
-18,763
-17,520
-15,871
Net Non Operating Interest Income Expense
204
204
161
-1,212
-491
Pretax Income
-14,412
-14,412
-19,372
-50,085
-16,271
Net Income Common Stockholders
-14,412
-14,412
-19,372
-50,085
-16,271
Diluted NI Available to Com Stockholders
-14,412
-14,412
-19,372
-50,085
-16,271
Basic EPS
-0.10
-0.07
-0.10
-0.63
-0.08
Diluted EPS
-0.10
-0.07
-0.10
-0.63
-0.08
Basic Average Shares
194,653.91
197,111.57
194,588.25
79,637.96
194,584.52
Diluted Average Shares
194,653.91
197,111.57
194,588.25
79,637.96
194,584.52
Total Operating Income as Reported
-14,805
-14,805
-18,763
-17,520
-15,871
Rent Expense Supplemental
189
189
132
129
132
Total Expenses
16,008
16,008
19,401
20,089
17,662
Net Income from Continuing & Discontinued Operation
-14,412
-14,412
-19,372
-50,085
-16,271
Normalized Income
-14,749
-14,749
-17,960
-18,553
-16,050
Interest Income
242
242
191
--
--
Interest Expense
38
38
30
1,212
491
Net Interest Income
204
204
161
-1,212
-491
EBIT
-14,374
-14,374
-19,342
-48,873
-15,780
EBITDA
-13,787
-13,787
-18,849
-48,359
-14,560
Reconciled Cost of Revenue
500
500
351
1,315
1,142
Reconciled Depreciation
587
587
493
514
1,220
Net Income from Continuing Operation Net Minority Interest
-14,412
-14,412
-19,372
-50,085
-16,271
Total Unusual Items Excluding Goodwill
337
337
-1,412
-31,532
-221
Total Unusual Items
337
337
-1,412
-31,532
-221
Normalized EBITDA
-14,124
-14,124
-17,437
-16,827
-14,339
12/31/2020 - 12/6/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade